 |
A recent press release from Foamix gives a view into how well Finacea Foam is selling. Based on Q1 2016 sales of the newly approved Finacea Foam, Bayer HealthCare made a royalty payment of $682,000 to Foamix as a fee for licensing their foaming technology.
Along with the comment that Finacea Foam sales are continuing to grow, it seems that Finacea Foam is doing well so far as a product.
There has been little feedback from users of Finacea Foam so far. If you have tried it, do please leave us some comments here – Finacea Foam Reviews.
Foamix Reports First Quarter 2016 Financial Results and Provides Business Update
U.S. Sales of Finacea Foam, azelaic acid 15%, continue to grow. The royalty payment from Bayer HealthCare AG for Finacea Foam for Q1, 2016 was $682,000, up 170% from the fourth quarter of 2015.
Finacea Foam was developed as part of a research and development collaboration between Foamix and Bayer, utilizing Foamix’s proprietary foam technology platform. The drug was launched by Bayer in the USA in September, 2015.
